These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15543343)

  • 1. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
    Sebestjen M; Keber I; Zegura B; Simcic S; Bozic M; Fressart MM; Stegnar M
    Thromb Haemost; 2004 Nov; 92(5):1129-35. PubMed ID: 15543343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia.
    Sebestjen M; Zegura B; Keber I
    J Intern Med; 2002 Jan; 251(1):77-85. PubMed ID: 11851868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.
    Wang TD; Chen WJ; Lin JW; Cheng CC; Chen MF; Lee YT
    Atherosclerosis; 2003 Oct; 170(2):315-23. PubMed ID: 14612213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.
    Ural AU; Yilmaz MI; Avcu F; Yalcin A
    Int J Hematol; 2002 Oct; 76(3):279-83. PubMed ID: 12416740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.
    Okopien B; Huzarska M; Kulach A; Stachura-Kulach A; Madej A; Belowski D; Zielinski M; Herman ZS
    J Cardiovasc Pharmacol; 2005 Feb; 45(2):160-4. PubMed ID: 15654265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids.
    Shinn AH; Carr-Lopez SM; Smith JW; Elledge EA; Smith TJ
    Curr Med Res Opin; 2005 Feb; 21(2):207-14. PubMed ID: 15801991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
    Zeman M; Zák A; Vecka M; Tvrzická E; Písaríková A; Stanková B
    Cas Lek Cesk; 2005; 144(11):737-41. PubMed ID: 16335699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination.
    Zeman M; Zák A; Vecka M; Tvrzická E; Písaríková A; Stanková B
    J Nutr Biochem; 2006 Jun; 17(6):379-84. PubMed ID: 16214329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate.
    Hayakawa T; Shimoyama K; Sekiya S; Sekiguchi M; Inotsume N
    Yakugaku Zasshi; 2002 Dec; 122(12):1145-51. PubMed ID: 12510391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
    Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Choi IS; Shin EK
    J Am Coll Cardiol; 2005 May; 45(10):1649-53. PubMed ID: 15893182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term treatment of combined hyperlipidemia with a combination of fluvastatin and fenofibrate].
    Widimský J; Hulínský V; Balazovjech I; Lánská V
    Vnitr Lek; 1999 Apr; 45(4):210-6. PubMed ID: 11045181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM
    Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural honey lowers plasma glucose, C-reactive protein, homocysteine, and blood lipids in healthy, diabetic, and hyperlipidemic subjects: comparison with dextrose and sucrose.
    Al-Waili NS
    J Med Food; 2004; 7(1):100-7. PubMed ID: 15117561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cerivastatin-a new synthetic 3-hydroxy-3-methylglutaryl (HMG) inhibitor: effect of 0,2 mg dose in patients with primary hyperlipidemias].
    Solov'eva EIu; Rozhkova TA; Tvorogova MG; Kukharchuk VV
    Ter Arkh; 1999; 71(8):30-4. PubMed ID: 10515032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
    Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
    Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
    Stulc T; Melenovský V; Grauová B; Kozich V; Ceska R
    Nutrition; 2001 Sep; 17(9):721-3. PubMed ID: 11527658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.